摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3-(2-naphthamido)-4-(3-chlorophenyl)butanoic acid | 1227832-66-7

中文名称
——
中文别名
——
英文名称
(R)-3-(2-naphthamido)-4-(3-chlorophenyl)butanoic acid
英文别名
(3R)-4-(3-chlorophenyl)-3-(naphthalene-2-carbonylamino)butanoic acid
(R)-3-(2-naphthamido)-4-(3-chlorophenyl)butanoic acid化学式
CAS
1227832-66-7
化学式
C21H18ClNO3
mdl
——
分子量
367.832
InChiKey
ZYFOGIZDBANPAZ-LJQANCHMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    26
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    66.4
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (R)-3-氨基-4-(3-氯苯基)丁酸2-萘甲酰氯 在 sodium carbonate 作用下, 以 乙腈 为溶剂, 反应 16.0h, 生成 (R)-3-(2-naphthamido)-4-(3-chlorophenyl)butanoic acid
    参考文献:
    名称:
    Structure-based design of novel human Pin1 inhibitors (II)
    摘要:
    Following the discovery of a novel series of phosphate-containing small molecular Pin1 inhibitors, the drug design strategy shifted to replacement of the phosphate group with an isostere with potential better pharmaceutical properties. The initial loss in potency of carboxylate analogs was likely due to weaker charge-charge interactions in the putative phosphate binding pocket and was subsequently recovered by structure-based optimization of ligand-protein interactions in the proline binding site, leading to the discovery of a sub-micromolar non-phosphate small molecular Pin1 inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.02.033
点击查看最新优质反应信息

文献信息

  • Structure-based design of novel human Pin1 inhibitors (II)
    作者:Liming Dong、Joseph Marakovits、Xinjun Hou、Chuangxing Guo、Samantha Greasley、Eleanor Dagostino、RoseAnn Ferre、M. Catherine Johnson、Eugenia Kraynov、James Thomson、Ved Pathak、Brion W. Murray
    DOI:10.1016/j.bmcl.2010.02.033
    日期:2010.4
    Following the discovery of a novel series of phosphate-containing small molecular Pin1 inhibitors, the drug design strategy shifted to replacement of the phosphate group with an isostere with potential better pharmaceutical properties. The initial loss in potency of carboxylate analogs was likely due to weaker charge-charge interactions in the putative phosphate binding pocket and was subsequently recovered by structure-based optimization of ligand-protein interactions in the proline binding site, leading to the discovery of a sub-micromolar non-phosphate small molecular Pin1 inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多